VolitionRx Ltd hails findings in first non-cancer NUQ study
VolitionRx Ltd has proved its technology's diagnostic potential outside cancer - as it reported positive findings in a pilot study looking at a deadly lung disease.
Company
NYSE:VNRX
VolitionRx Limited is a multi-national epigenetics company developing simple, easy-to-use, cost-effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients but also to improve their quality of life. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics. Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.
89 stories · page 4 of 5
VolitionRx Ltd has proved its technology's diagnostic potential outside cancer - as it reported positive findings in a pilot study looking at a deadly lung disease.
Some significant movers on Thursday at 9.30am, including Stratmin Global and Victoria Oil & Gas..
In a study of 430 patients in Denmark, the test accurately detected 75% of colorectal adenomas
The stage is set for a catalyst-packed 2016 for cancer diagnostics firm VolitionRx, reckons research house Edison.
Motive Television, VolitionRx and Jersey Oil & Gas were also in the news
Diagnostics specialist VolitionRx has hired a full-time head of US operations as it prepares to introduce its NuQ blood tests for cancer stateside and around the globe.
VolitionRx's tests are based on the science of nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.
Investments and investor services
Making Tuesday’s news highlights: Rex Bionics, VolitionRx, CentralNic, Challenger Acquisitions, Atlantis Resources, fastjet, and several others.
A panel test of four NuQ biomarker assays, adjusted for age, detected 91% of colorectal cancer cases
At the conference, David Kratochvil, chief financial officer and treasurer, and Scott Powell, vice president of IR, will outline the company’s business milestones
Aside from the Fed and interest rates, what else is trending...?
Archive
Highlights of the news developments from the growth companies universe
Below are the main news driven share price changes at 10:17 a.m. in New York on Thursday:
Lung cancer is the second most common form and smoking history is the most important of the known and proven risk factors.
Investments and investor services
Here we take our daily look at the small cap news highlights of the trading day
The new patent covers the methods for measuring nucleosome-protein bonds
VolitionRx (NYSE:VNRX) has been granted a second US patent for its test to detect cancer through changes in nucleosomes.
Below are the main news driven share price changes at 10:50 a.m. in New York on Thursday:
Cancer test developer VolitionRx (NYSE:VNRX) revealed that chief executive Cameron Reynolds will at two conferences this month (November) to discuss the business's progress.
Archive
Pride of place goes to Plethora Solutions, after Jim Mellon's Regent Pacific offered to take it over.